MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
| Revenue (TTM) | $157.08M |
| Gross Profit (TTM) | $-30.23M |
| EBITDA | $-56.57M |
| Operating Margin | -161.00% |
| Return on Equity | -140.30% |
| Return on Assets | -18.00% |
| Revenue/Share (TTM) | $2.48 |
| Book Value | $0.88 |
| Price-to-Book | 13.58 |
| Price-to-Sales (TTM) | 1.83 |
| EV/Revenue | 1.084 |
| EV/EBITDA | -1.54 |
| Quarterly Earnings Growth (YoY) | -70.40% |
| Quarterly Revenue Growth (YoY) | 57.50% |
| Shares Outstanding | $63.56M |
| Float | $55.60M |
| % Insiders | 3.43% |
| % Institutions | 70.16% |
Volatility is currently expanding